[{"orgOrder":0,"company":"NeOnc Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NEO212","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeOnc Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NeOnc Technologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NeOnc Technologies \/ Inapplicable"},{"orgOrder":0,"company":"NeOnc Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NEO100","moa":"Farnesyl transferase","graph1":"Oncology","graph2":"Phase II","graph3":"NeOnc Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeOnc Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeOnc Technologies \/ Inapplicable"},{"orgOrder":0,"company":"NeOnc Technologies","sponsor":"Anova Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"VIETNAM","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Perillyl Alcohol","moa":"GTPase NRas (NRAS)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeOnc Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"NeOnc Technologies \/ Neonc Technologies","highestDevelopmentStatusID":"7","companyTruncated":"NeOnc Technologies \/ Neonc Technologies"},{"orgOrder":0,"company":"NeOnc Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NEO100","moa":"Farnesyl transferase","graph1":"Oncology","graph2":"Phase I","graph3":"NeOnc Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"NeOnc Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeOnc Technologies \/ Inapplicable"}]